https://adreshe.com/en/a-cost-effectiveness-analysis-of-mosunetuzumab-vs-tisagenlecleucel-for-treatment-of-third-or-higher-line-3l-relapsed-or-refractory-r-r-follicular-lymphoma-fl-in-italy/ Health Economics & Outcomes Research Thu, 23 Oct 2025 13:14:16 +0000 hourly 1 https://wordpress.org/?v=6.9.4